“New Frontiers in Point-of-Care/POC Clinical Chemistry and Immunodiagnostic Testing: Business Challenges, Emerging Technologies, Competitive Landscape” is Venture Planning Group’s new report, which provides comprehensive analysis of the POC clinical chemistry markets, including their dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. Rationale The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient. Market Segmentation - Review of the POC clinical chemistry and immunodiagnostic market segments, including their dynamics, trends, structure, size, growth and major suppliers. - Five-year test volume and reagent sales forecasts clinical chemistry procedures by market segment:
- Physician Offices/Group Practices
- Emergency Rooms
- Operating/Recovery Suites
- ICUs/CCUs
- Cancer Clinics
- Ambulatory Care Centers
- Surgery Centers
- Nursing Homes
- Birth Centers Sales and Market Share Analysis - Sales and market shares of major reagent and instrument suppliers. Routine Clinical Chemistry Tests Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Blood Gases,
BUN (Blood Urea Nitrogen), Calcium, Cholesterol, Cholinesterase, Creatinine, CK-MB, Electrolytes
(Carbon Dioxide/Bicarbonate, Chloride, Potassium, Sodium), Ferritin, Follate/Folic Acid, Fructosamine, GGT, Glucose, HDL, Iron, LDH, Magnesium, Phosphorus, Potassium, Protein, Sodium, Triglycerides, Troponin, Uric Acid, Urinalysis, Vitamin B12. Endocrine Function Tests Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,
Prolactin, T3, T3 Uptake, Free T3, T4, Free T4, TBG, Testosterone, TSH. Therapeutic Drug Monitoring (TDM) Tests Amikacin, Carbamazepine, Digoxin, Gentamicin, Lidocaine, Lithium, Methotrexate,
Phenobarbital, Phenytoin/Dilatin, NAPA/Procainamide, Quinidine, Theophylline, Tobramycin,
Valproic Acid, Vancomycin. Immunoprotein Tests C3, C4, CRP, IgA, IgE Soecific, IgE Total, IgG, Immunoglobulins, Protein Electrophoresis,
and others. Drugs of Abuse Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,
LSD, Methadone, Methaqualone, Opiates, Phencyclidine, Propoxyphene, and others. Technology Review - Emerging technologies and their applications for POC testing. - Comprehensive listings of companies developing or marketing POC diagnostic technologies
and products, by test. Strategic Recommendations - Specific opportunities for new POC instruments and reagent systems with potentially
significant market appeal during the next five years. - Design criteria for POC testing products. - Alternative business expansion strategies. - Potential market entry barriers and risks. Competitive Assessments - Assessments of major suppliers and emerging market entrants, including their sales, product
portfolios, marketing tactics, joint ventures, and new products in R&D. - The companies analyzed in the report include: - Abbott
- AdnaGen
- Agilent Technologies
- Beckman Coulter/Danaher
- Biomedical Diagnostics
- Biomerieux
- Bio-Rad
- Diasorin
- Eiken Chemical
- Fujirebio/Innogenetics
- Grifols
- Instrumentation Laboratory
- Kyowa Medex
- Matritech/Alere
- Ortho-Clinical Diagnostics
- Quest Diagnostics
- Roche
- Siemens
- Sysmex
- ThermoFisher/Life Technologies
- Tosoh
- Wako
- Wallac/PE Methodology This report is based on a combination of primary and secondary sources of information, including review of recent technical and business publications, manufacturer product literature, industry analyst reports, and Venture Planning Group's proprietary data files. Contains 645 pages and 175 tables
|